Bio-Rad Laboratories FY 2022: revenue $2.8B, down 4%; diluted EPS −$121.79

Key figures from this report

These are the numbers Bio-Rad Laboratories reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

1. Revenue$2.8B−4% from $2.9B in FY 202110-K income statement, on EDGAR
2. Net income−$3.6B−185% from $4.2B in FY 202110-K income statement, on EDGAR
3. Diluted EPS−$121.79−187% from $140.56 in FY 202110-K income statement, on EDGAR
4. Cash and cash equivalents$434.2M−8% from $470.8M in FY 2021Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
5. Cash from operations$194.4M−70% from $656.5M in FY 202110-K cash flow statement, on EDGAR

Every year in the financial tables